Napp receives approval from MHRA to prescribe Targinact® for the treatment of RLS

Napp Pharmaceuticals Limited has announced that Targinact, a fixed combination of prolonged-release oxycodone/naloxone, has received approval for use in the UK. This follows the European Commission's positive decision in January 2015 to recommend Targinact as a second line symptomatic treatment for patients with severe to very severe idiopathic restless legs syndrome (RLS), after failure of dopaminergic therapy. (1,2)
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: Tags: *** Editor's Pick Practical therapeutics Industry News Neurology dopaminergic therapy idiopathic restless leg syndrome Latest News oxycodone/naloxone targinact Source Type: news